Las Vegas (PRWEB) January 16, 2013
Convoy Therapeutics, a subsidiary of ACTUS Biotechnologies, is proud to announce the relaunching of their website. The revised website includes new information regarding the company's platform technology and development programs.
The interactive website provides a user-friendly platform for interested parties to gather information regarding Convoy Therapeutics’ innovative platform technology and its various uses in enabling the penetration of macromolecules and retention of small molecules in the skin for a wide variety of cosmetic and therapeutic uses.
“The revamped website offers comprehensive information regarding Convoy’s ground-breaking technology and how it can be applied in a variety of uses in cosmetic and therapeutic applications,” says Dr. Robert Davis, Chief Business Officer of Convoy Therapeutics. “Perhaps more importantly, it shows the incredible healing opportunities possible when combining other therapies with our skin-penetrating technologies.” Convoy Therapeutics’ main objective is to provide a platform for effective and efficient drug, cosmeceutical, or active delivery into the skin. “The website demonstrates the difference between the previous systems of skin delivery and Convoy’s technology,” adds Dr. Davis.
The newly designed website includes diagrams, videos, and slide presentations that visually demonstrate the Convoy technology penetrating the outer layers of the skin, delivering therapeutic macromolecules. Treatment areas include: dermatology, immunology, vaccinations, and cancer. The website also contains information regarding the company's development pipeline including: CY-102, a reformulated Cyclosporine for topical use in treating psoriasis currently in late stage development, and HA-102PH, a topical cosmetic preparation of hyaluronic acid for enhanced skin tone and hydration also in the later development stages.
Copyright©2012 Vocus, Inc.
All rights reserved